Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia
- PMID: 38167251
- PMCID: PMC10759368
- DOI: 10.1186/s13195-023-01367-7
Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia
Abstract
Background: Disease-modifying treatments for Alzheimer's disease highlight the need for early detection of cognitive decline. However, at present, most primary care providers do not perform routine cognitive testing, in part due to a lack of access to practical cognitive assessments, as well as time and resources to administer and interpret the tests. Brief and sensitive digital cognitive assessments, such as the Digital Clock and Recall (DCR™), have the potential to address this need. Here, we examine the advantages of DCR over the Mini-Mental State Examination (MMSE) in detecting mild cognitive impairment (MCI) and mild dementia.
Methods: We studied 706 participants from the multisite Bio-Hermes study (age mean ± SD = 71.5 ± 6.7; 58.9% female; years of education mean ± SD = 15.4 ± 2.7; primary language English), classified as cognitively unimpaired (CU; n = 360), mild cognitive impairment (MCI; n = 234), or probable mild Alzheimer's dementia (pAD; n = 111) based on a review of medical history with selected cognitive and imaging tests. We evaluated cognitive classifications (MCI and early dementia) based on the DCR and the MMSE against cohorts based on the results of the Rey Auditory Verbal Learning Test (RAVLT), the Trail Making Test-Part B (TMT-B), and the Functional Activities Questionnaire (FAQ). We also compared the influence of demographic variables such as race (White vs. Non-White), ethnicity (Hispanic vs. Non-Hispanic), and level of education (≥ 15 years vs. < 15 years) on the DCR and MMSE scores.
Results: The DCR was superior on average to the MMSE in classifying mild cognitive impairment and early dementia, AUC = 0.70 for the DCR vs. 0.63 for the MMSE. DCR administration was also significantly faster (completed in less than 3 min regardless of cognitive status and age). Among 104 individuals who were labeled as "cognitively unimpaired" by the MMSE (score ≥ 28) but actually had verbal memory impairment as confirmed by the RAVLT, the DCR identified 84 (80.7%) as impaired. Moreover, the DCR score was significantly less biased by ethnicity than the MMSE, with no significant difference in the DCR score between Hispanic and non-Hispanic individuals.
Conclusions: DCR outperforms the MMSE in detecting and classifying cognitive impairment-in a fraction of the time-while being not influenced by a patient's ethnicity. The results support the utility of DCR as a sensitive and efficient cognitive assessment in primary care settings.
Trial registration: ClinicalTrials.gov identifier NCT04733989.
Keywords: Alzheimer’s disease; Clock Drawing Test; Cognitive screening; Dementia; Digital cognitive assessment; Mild cognitive impairment; Mild neurocognitive disorder; Mini-Mental State Examination; Neurocognitive disorder; Rey Auditory Verbal Learning Test.
© 2023. The Author(s).
Conflict of interest statement
APL is a co-founder and Chief Medical Officer of Linus Health and a co-founder of TI Solutions and declares ownership of shares or share options in the company. APL serves as a paid member of the scientific advisory boards for Neuroelectrics, Magstim Inc., TetraNeuron, Skin2Neuron, MedRhythms, and Hearts Radiant. DB is a co-founder and Chief Executive Officer of Linus Health and declares ownership of shares or share options in the company. JS is Chief Product Officer of Linus Health and declares ownership of shares or share options in the company. All other authors are employees of Linus Health and declare ownership of shares or share options in the company.
Figures





Similar articles
-
Detecting functional impairment with the Digital Clock and Recall.J Alzheimers Dis. 2024 Nov;102(2):329-337. doi: 10.1177/13872877241290123. Epub 2024 Nov 12. J Alzheimers Dis. 2024. PMID: 39533697
-
Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults.BMC Geriatr. 2015 Sep 7;15:107. doi: 10.1186/s12877-015-0103-3. BMC Geriatr. 2015. PMID: 26346644 Free PMC article.
-
Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI).Cochrane Database Syst Rev. 2021 Jul 27;7(7):CD010783. doi: 10.1002/14651858.CD010783.pub3. Cochrane Database Syst Rev. 2021. PMID: 34313331 Free PMC article.
-
A Stable and Scalable Digital Composite Neurocognitive Test for Early Dementia Screening Based on Machine Learning: Model Development and Validation Study.J Med Internet Res. 2023 Dec 1;25:e49147. doi: 10.2196/49147. J Med Internet Res. 2023. PMID: 38039074 Free PMC article.
-
Is the Montreal Cognitive Assessment (MoCA) screening superior to the Mini-Mental State Examination (MMSE) in the detection of mild cognitive impairment (MCI) and Alzheimer's Disease (AD) in the elderly?Int Psychogeriatr. 2019 Apr;31(4):491-504. doi: 10.1017/S1041610218001370. Epub 2018 Nov 14. Int Psychogeriatr. 2019. PMID: 30426911
Cited by
-
Usage patterns of cognitive assessments during Medicare's Annual Wellness Visit: A national survey.Alzheimers Dement. 2025 Feb;21(2):e14539. doi: 10.1002/alz.14539. Epub 2025 Jan 17. Alzheimers Dement. 2025. PMID: 39822164 Free PMC article.
-
Independent validation and outlier analysis of EuroPOND alzheimer's disease staging model using ADNI and real-world clinical data.Alzheimers Res Ther. 2025 Jun 16;17(1):134. doi: 10.1186/s13195-025-01788-6. Alzheimers Res Ther. 2025. PMID: 40524264 Free PMC article.
-
Digital Assessment of Cognitive Health in Outpatient Primary Care: Usability Study.JMIR Form Res. 2025 Mar 12;9:e66695. doi: 10.2196/66695. JMIR Form Res. 2025. PMID: 40073397 Free PMC article.
-
Potential Value of Plasma-Based Biomarkers for Prediction of Episodic Memory Performance and Identification of Individuals with Amnestic Mild Cognitive Impairment.Neuropsychiatr Dis Treat. 2025 May 5;21:999-1010. doi: 10.2147/NDT.S516476. eCollection 2025. Neuropsychiatr Dis Treat. 2025. PMID: 40352958 Free PMC article.
-
PENSIEVE-AI a brief cognitive test to detect cognitive impairment across diverse literacy.Nat Commun. 2025 Mar 23;16(1):2847. doi: 10.1038/s41467-025-58201-x. Nat Commun. 2025. PMID: 40122854 Free PMC article.
References
-
- World Health Organization. WHO Disability and Health Fact Sheet. Cited 2023 Apr 10. Available from: https://apps.who.int/iris/rest/bitstreams/1343030/retrieve.
-
- Nichols E, Steinmetz JD, Vollset SE, Fukutaki K, Chalek J, Abd-Allah F, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105–e125. doi: 10.1016/S2468-2667(21)00249-8. - DOI - PMC - PubMed
-
- Gaugler J, Bryan James TJ, Reimer J, Weuve J. Alzheimer’s Disease Facts and Figures, 17. Alzheimer’s Dementia: Chicago, IL; 2021.
-
- Eisai Inc. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease. clinicaltrials.gov; 2022 . Cited 2023 May 16. Report No.: NCT03887455. Available from: https://clinicaltrials.gov/ct2/show/NCT03887455.
-
- A Study of Donanemab (LY3002813) in Participants With Early Alzheimer’s Disease (TRAILBLAZER-ALZ 2) - Full Text View - ClinicalTrials.gov. Cited 2023 May 17. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04437511.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical